(0.99%) 5 068.30 points
(0.96%) 38 265 points
(1.52%) 15 843 points
(0.14%) $79.11
(5.59%) $2.04
(0.23%) $2 316.20
(0.80%) $26.96
(1.13%) $965.65
(-0.10%) $0.932
(-0.38%) $10.99
(-0.11%) $0.798
(-1.41%) $91.95
Quarter results tomorrow
(bmo 2024-05-03)
Expected move: +/- 12.02%
@ $7.86
Išleistas: 14 vas. 2024 @ 22:07
Grąža: -28.58%
Ankstesnis signalas: vas. 14 - 19:00
Ankstesnis signalas:
Grąža: 1.62 %
Live Chart Being Loaded With Signals
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases...
Stats | |
---|---|
Šios dienos apimtis | 947 381 |
Vidutinė apimtis | 1.95M |
Rinkos kapitalizacija | 461.34M |
EPS | $0 ( 2024-02-28 ) |
Kita pelno data | ( $-0.650 ) 2024-05-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.78 |
ATR14 | $0.0100 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-02 | Lucera Erick | Buy | 25 966 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 35 300 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 106 000 | Stock Option (right to buy) |
2024-03-02 | Burkly Linda | Buy | 15 055 | Common Stock |
2024-03-02 | Burkly Linda | Buy | 74 400 | Stock Option (right to buy) |
INSIDER POWER |
---|
88.65 |
Last 95 transactions |
Buy: 4 455 498 | Sell: 157 736 |
Tūris Koreliacija
Editas Medicine Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
RMRM | 0.931 |
SLDB | 0.86 |
QRTEA | 0.851 |
OSS | 0.851 |
ATRA | 0.845 |
SNOA | 0.843 |
DNLI | 0.841 |
PDCO | 0.841 |
INCY | 0.841 |
CNCR | 0.84 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Editas Medicine Inc Koreliacija - Valiuta/Žaliavos
Editas Medicine Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $78.12M |
Bruto pelnas: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2023 |
Pajamos: | $78.12M |
Bruto pelnas: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2022 |
Pajamos: | $19.71M |
Bruto pelnas: | $13.38M (67.85 %) |
EPS: | $-2.98 |
FY | 2021 |
Pajamos: | $25.54M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.85 |
Financial Reports:
No articles found.
Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.